Veronica Sanchez Bulis sold $4,103 of LYEL
VP, Corporate Controller at Lyell Immunopharma, Inc.. 217 shares at an average of $18.91, traded May 11, 2026, filed Jun 15, 2026.
Score components
- +15RoleOfficer
- 0Trade size$4k at market
- 0Share of holdings soldSold 1.4% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002095702-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 11, 2026 | SOpen-market sale Common Stock | -217 | $18.91 | $4,103 | 15,420 | Jun 15, 2026 |
Related signals
Other insiders at Lyell Immunopharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | LYELsell Lyell Immunopharma, Inc. | David Shook Chief Medical Officer | $6,350 500 shares | -2% | |
| 35Weak | Lyell Immunopharma, Inc. | Stephen J. Hill Chief Operating Officer | $15k 989 shares | -6% | |
| 30Weak | Lyell Immunopharma, Inc. | Gary K. Lee Chief Scientific Officer | $23k 1,457 shares | -8% | |
| 56Moderate | Lyell Immunopharma, Inc. | Lynn Seely President and CEO | $149k 9,589 shares | -13% | |
| 30Weak | Lyell Immunopharma, Inc. | Veronica Sanchez Bulis VP, Corporate Controller | $8,905 621 shares | -4% | |
| 35Weak | Lyell Immunopharma, Inc. | Stephen J. Hill Chief Operating Officer | $1,276 89 shares | -0% | |
| 30Weak | Lyell Immunopharma, Inc. | Gary K. Lee Chief Scientific Officer | $1,879 131 shares | -1% | |
| 40Moderate | Lyell Immunopharma, Inc. | Lynn Seely President and CEO | $5,593 390 shares | -1% | |
| 0Weak | Lyell Immunopharma, Inc. | Innovative Cellular Therapeutics Holdings Ltd owner | $137 10 shares | -0% | |
| 0Weak | Lyell Immunopharma, Inc. | Innovative Cellular Therapeutics Holdings Ltd owner | $137 10 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.